Medicare launched an 18-month pilot program in July offering three GLP-1 medications—Wegovy, Zepbound, and Foundayo—at $50 per month for eligible beneficiaries. The initiative represents a significant development, as federal law has historically barred Medicare from covering drugs prescribed solely for weight loss. The program targets Medicare Part D enrollees with a body mass index of 35 or higher, as well as those with a BMI between 27 and 34 who have specific health conditions like prediabetes or cardiovascular disease.
However, the program contains a restriction that has created an unexpected barrier for some patients. The $50 discounted price applies exclusively to individuals using GLP-1 medications for weight loss alone. Patients who have a qualifying medical condition that the FDA has approved these drugs to treat—such as Type 2 diabetes or moderate to severe obstructive sleep apnea—are redirected to their standard Medicare Part D coverage. This means they may face copays ranging from hundreds to potentially over $600 monthly, undermining the affordability goal for some of the sickest patients.
Jeff La Marca, a 68-year-old from New Jersey with severe obstructive sleep apnea and a BMI of 42, exemplifies this dilemma. Despite qualifying medically for weight loss treatment, his application was denied because his sleep apnea diagnosis—a condition the FDA recognizes GLP-1s can treat—disqualifies him from Bridge pricing. Medical professionals argue this creates an inequitable outcome, as patients with the greatest health needs are excluded from the discount program.
According to estimates by health policy analysts, approximately 3.8 million people qualify for the program. If enrollment reaches 25 percent and participants remain for the full 18 months, costs to Medicare could reach $3.3 billion, potentially rising to $10 billion with higher enrollment. CMS reported that initial authorization requests have been processed in under 12 hours in most cases, allowing thousands of eligible beneficiaries to access discounted medications. However, healthcare providers and policy experts contend that the program’s design leaves vulnerable patients facing unaffordable treatment options despite having established medical need.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI